Bicycle Therapeutics takes Roche's Genentech on an up to $2B immuno-oncology ride
Bicycle Therapeutics — which is developing a new class of chemically synthesized drugs designed to be pharmacologically as active as biologics, yet manufactured as small molecules — has scored another big partner: Roche’s Genentech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.